胶质瘤干细胞和干细胞的靶向免疫疗法

icartab

Glioblastoma stem cells and stem cell-targeting immunotherapies.

Advancements in immunotherapeutics promise new possibilities for the creation of glioblastoma (GBM) treatment options. Ongoing work in cancer stem cell biology has progressively elucidated the role of this tumor sub-population in oncogenesis and has distinguished them as prime therapeutic targets. Current clinical trials take a multifaceted approach with the intention of harnessing the intrinsic cytotoxic capabilities of the immune system to directly target glioblastoma cancer stem cells (gCSC) or indirectly disrupt their stromal microenvironment. Monoclonal antibodies (mAbs), dendritic cell (DC) vaccines, and chimeric antigen receptor (CAR) T cell therapies have emerged as the most common approaches, with particular iterations incorporating cancer stem cell antigenic markers in their treatment designs. Ongoing work to determine the comprehensive antigenic profile of the gCSC in conjunction with efforts to counter the immunosuppressive tumor microenvironment holds much promise in future immunotherapeutic strategies against GBM. Given recent advancements in these fields, we believe there is tremendous potential to improve outcomes of GBM patients in the continuing evolution of immunotherapies targeted to cancer stem cell populations in GBM.

胶质瘤干细胞和干细胞的靶向免疫疗法。

免疫治疗的优势为GBM的治疗展示了新的有可能的治疗方式。癌症干细胞生物学的进展已经逐步阐明肿瘤亚群在肿瘤发生中的作用，并且对其做了区分并将其作为首要的治疗目标。

目前的临床试验采用多途径的手段，利用免疫系统内在的毒性能力，直接靶向胶质肿瘤干细胞（gCSC）或者间接的破坏它们的基质微环境。单克隆抗体（单克隆抗体），树突状细胞（DC）疫苗，和嵌合抗原受体（CAR）的细胞疗法已经成为最常见的方法，尤其关注于癌症干细胞抗原标记物的设计。正在进行中的工作主要在于努力对抗免疫抑制肿瘤微环境的免疫治疗策略。鉴于最近在这些领域的进步，我们相信在靶向GBM肿瘤干细胞亚群的免疫治疗的开发方面会有很多巨大的潜力来改进GBM患者的治疗效果。

出自爱康得生物技术